DJO UK Ltd
7
3
4
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Post-Market Clinical Follow-up HVS on Increased Circulation, RPW2 and Cefar TENS
Role: lead
RCT on the Performance and Safety of LightForce® Therapy Lasers on Knee Osteoarthritis Pain Reduction (SPARK)
Role: lead
Observational Prospective PMCF Study to Confirm Performance and Safety of Intelect® Devices in Real World
Role: lead
Performance and Safety of LightForce® Therapy Lasers on Shoulder Soft Tissue Inflammation Pain Reduction
Role: lead
Performance and Safety of LightForce® Therapy Lasers on Lateral Ankle Sprain
Role: lead
Compex SP8.0 - Symptomatic Treatment of Musculoskeletal Pain
Role: lead
Cefar URO - Symptomatic Treatment of Overactive Bladder
Role: lead
All 7 trials loaded